Khun Prasert, 61, a retired school principal from Nakhon Ratchasima, had lived with type 2 diabetes for 18 years. He managed his blood sugar diligently. He checked his feet every night like his doctor told him. But one small cut on his heel — from a loose sandal strap — refused to heal. Six months later, it had become a chronic ulcer that was threatening his foot.
This is the hidden epidemic of diabetes in Thailand. We talk about blood sugar and insulin and diet. But the complication that lands more diabetic patients in Thai hospitals than any other is the one nobody wants to discuss: wounds that simply will not close.
Over 800,000 Thais develop chronic diabetic wounds each year. About 15% of them will eventually face amputation. It’s a cascade that starts small — a blister, a crack in the skin, a cut from trimming toenails — and ends with a life-changing surgery that could have been prevented.
Why Diabetic Wounds Refuse to Heal
Normal wound healing is an orchestrated biological symphony. Platelets arrive first to stop the bleeding. Then immune cells clean out bacteria and debris. Then fibroblasts lay down new collagen. Then new blood vessels grow into the wound bed to deliver oxygen and nutrients. Then the skin edges pull together and close. It’s elegant. It’s efficient. And in a healthy person, it works the same way every time.
Diabetes throws sand into every gear of this machine.
High blood glucose damages the endothelial cells that line blood vessels, reducing circulation to the extremities. The immune cells that should clear infection become sluggish and ineffective — a phenomenon called immune senescence. The fibroblasts that should build new tissue are operating on diminished resources. And the growth factors that coordinate the whole process? Their signaling pathways are blunted.
The result is a wound stuck in the inflammatory phase — open, vulnerable, and dangerously close to infection.
The Exosome Advantage: Healing Without Replacing Cells
One of the most exciting developments in wound healing research isn’t the stem cells themselves — it’s what they secrete. Mesenchymal stem cells release extracellular vesicles, often called exosomes, that carry a cargo of microRNAs, growth factors, and anti-inflammatory signals directly into damaged tissue.
A May 2026 study in the Journal of Functional Biomaterials demonstrated something remarkable: when dental pulp stem cells were grown in a 3D fibrin/gelatin hydrogel — a structure that mimics the body’s natural tissue environment — the exosomes they produced were dramatically more potent than those from standard 2D cell culture. These “3D-primed” exosomes accelerated diabetic wound closure in preclinical models by enhancing both angiogenesis (new blood vessel growth) and immune modulation at the wound site.
Think of it this way: the exosomes aren’t doing the healing themselves. They’re delivering a genetic instruction manual that tells the patient’s own cells how to restart the stalled healing process. The wound already has all the cells it needs — fibroblasts, endothelial cells, keratinocytes. They’re just not getting the right signals. Exosomes deliver those signals.
A parallel 2026 review in Periodontology 2000 catalogued the growing body of evidence showing that exosome-based therapies consistently outperform cell-free controls in diabetic wound models — reducing wound area by 40-60% more than standard dressings alone. That’s the difference between a wound that closes in weeks versus one that festers for months.
What This Means for Patients at Our Bangkok Clinic
We’ve integrated these insights into our wound healing protocol. Rather than a one-size-fits-all approach, we assess each patient’s wound profile — size, depth, infection status, vascular supply — and design a tailored regenerative strategy.
For Khun Prasert, that meant a combination of local MSC-derived exosome application directly to the wound bed, combined with systemic MSC infusion to address the underlying circulatory and immune dysfunction. The exosomes did the local work — signaling fibroblasts to produce collagen, recruiting endothelial cells to build new capillaries, suppressing the chronic inflammation that was keeping the wound open. The systemic infusion addressed the bigger picture — improving overall vascular function and immune competence.
Within four weeks, his wound had reduced in area by 70%. By week eight, it was fully closed. He still has diabetes. He still manages his blood sugar every day. But he still has his foot — and he still walks to the morning market in Nakhon Ratchasima every Saturday with his wife.
This isn’t a one-off result. Across our wound care patients, we’re seeing closure rates that exceed what standard wound care alone can deliver. The combination of targeted exosome therapy and systemic MSC support addresses both the local wound environment and the systemic dysfunction that created it in the first place.
The Cost of Waiting vs. The Cost of Acting
In Thailand, a diabetic foot ulcer that progresses to amputation costs the healthcare system approximately 300,000-500,000 THB in direct medical expenses — and that doesn’t account for the loss of mobility, independence, and quality of life that follows. Our regenerative wound protocol starts at approximately 120,000 THB (about $3,300 USD), depending on wound severity and the number of sessions required.
This isn’t just about saving money. It’s about saving limbs — and the lives that go with them.
FAQ
Is this treatment painful?
The exosome application is topical — applied directly to the wound surface — so there’s minimal discomfort. The IV MSC infusion is a standard intravenous procedure. Most patients find it significantly less painful than the wound debridement procedures they’re already familiar with.
How many sessions will I need?
Most patients receive 2-4 exosome applications at weekly intervals combined with 1-2 systemic MSC infusions. Larger or more chronic wounds may require additional sessions. We assess progress at each visit and adjust the protocol accordingly.
Does it work for all types of chronic wounds?
The strongest evidence is for diabetic foot ulcers, but the same mechanisms — angiogenesis, immune modulation, fibroblast activation — apply to pressure ulcers, venous stasis ulcers, and other chronic wound types. We evaluate each case individually.
Is it covered by Thai health insurance?
Currently, most Thai insurance plans do not cover regenerative wound therapy. We provide full cost transparency upfront and can discuss payment options during your consultation.
References
- Qiao, X., et al. (2026). 3D Fibrin/Gelatin Hydrogel System Enhances the Therapeutic Potency of DPSC-Derived Extracellular Vesicles Compared to 2D Culture in Accelerating Diabetic Wound Healing via Angiogenesis and Immune Modulation. Journal of Functional Biomaterials, 17(5). https://doi.org/10.3390/jfb17050244
- Ahmad, P., et al. (2026). Understanding Exosomes in Diabetic Wound Healing. Periodontology 2000, 92(1). https://doi.org/10.1111/prd.70055
Don’t let a wound that won’t heal determine your future. Schedule a free wound assessment at our Bangkok clinic. Visit cell-lavie.com/contact — the sooner you act, the more options you have.